Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Metabolic Syndrome: Development of the Issue, Main Diagnostic Criteria

https://doi.org/10.20996/1819-6446-2018-14-5-757-764

Full Text:

Abstract

Obesity is one of the leading and the most serious risk factors of cardiovascular diseases. Overweight provokes many metabolic and hemodynamic disorders.  About 30% of inhabitants of the planet have overweight and prevalence of obesity increases by 10% every 10 years according to the WHO data.  The probability of arterial hypertension in obese  patients is 50% higher than in people with normal body mass. Framingham study showed that obesity is an independent, significant risk factor  of ischemic heart  disease, myocardial infarction, cerebral stroke  and  diabetes mellitus. The most dangerous is the central obesity with the preferential fat deposition in the abdomen. Combination of visceral obesity, violation of carbohydrate and lipid metabolism, arterial hypertension, and close pathogenic relationship between these  factors  underlie the isolated symptom complex known  as metabolic syndrome. J. Vague was the first to describe relationship between abdominal obesity with cardiovascular disease and mortality in 1947. In our country G.F. Lang noticed common combination of arterial hypertension with obesity, lipid and carbohydrate metabolism disorders. Thus, metabolic syndrome significantly increases risk and  severity of cardiovascular disease. Within last decades criteria of metabolic syndrome stays constant. The factors  of insulin resistance and  endothelial dysfunction as stages of the pathogenesis of the metabolic syndrome have been  studied in detail. The mechanisms of insulin resistance and endothelial dysfunction are discussed in detail in this article as well as inflammatory markers and the significance of highly sensitive C-reactive protein.

About the Authors

Yu. N. Belenkov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Yuriy N. Belenkov – MD, PhD, Professor, Academician of the Russian Academy of Sciences, Head of Chair of Hospital Therapy №1, Medical Faculty.

Trubetskaya ul. 8-2, Moscow, 119991.

 



E. V. Privalova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Elena V. Privalova – MD, PhD, Professor, Chair of Hospital Therapy №1, Medical Faculty.

Trubetskaya ul. 8-2, Moscow, 119991.

 



V. Y. Kaplunova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Vera Y. Kaplunova – MD, PhD, Associate Professor, Chair of Hospital Therapy №1, Medical Faculty.

Trubetskaya ul. 8-2, Moscow, 119991.

 



V. Y. Zektser
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Vita Y. Zektser – MD, PhD, Assistant, Chair of Hospital Therapy №1, Medical Faculty.

Trubetskaya ul. 8-2, Moscow, 119991.

 



N. N. Vinogradova
City Clinical Hospital named after A.K. Yeramishantsev
Russian Federation

Natalya N. Vinogradova – MD, Therapist.

Lenskaya ul. 15,  Moscow, 129327.

 



I. S. Ilgisonis
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Irina S. Ilgisonis – MD, PhD, Associate Professor, Chair of Hospital Therapy №1, Medical Faculty.

Trubetskaya ul. 8-2, Moscow, 119991.

 



G. A. Shakaryants
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Gayane A. Shakaryants - MD, PhD, Assistant, Chair of Hospital Therapy №1, Medical Faculty.

Trubetskaya ul. 8-2, Moscow, 119991.

 



M. V. Kozhevnikova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Maria V. Kozhevnikova - MD, PhD, Assistant, Chair of Hospital Therapy №1, Medical Faculty.

Trubetskaya ul. 8-2, Moscow, 119991.

 



A. S. Lishuta
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Alexey S. Lishuta – MD, PhD, Associate Professor, Chair of Hospital Therapy №1, Medical Faculty.

Trubetskaya ul. 8-2, Moscow, 119991.



References

1. Diagnosis and treatment of metabolic syndrome, Russian recommendations. 2nd revision (2009). [cited by Oct 10, 2018]. Available from: http://www.scardio.ru/content/images/recommendation/nacionalnye_rekomendacii_po_diagnostike_i_lecheniyu_metabolicheskogo_sindroma.pdf. (In Russ.).

2. Rothberg G.E., ed. Metabolic syndrome. Moscow: MED-M54 press-inform; 2007. (In Russ.).

3. Lang G.F. Hypertonic disease. Leningrad: Medgiz; 1950. (In Russ.) [Ланг Г.Ф. Гипертоническая болезнь. Л.: Медгиз; 1950].

4. Myasnikov A.L. Hypertonic disease. Moscow: Medgiz; 1954. (In Russ.).

5. Henefeld M., Leonhardt W. Das metabolische Sindrome. Deusch Ges Wes. 1980;36:545-51.

6. Reaven G.M. Lecture role of insulin resistense in human disease. Diabetes. 1988;37:1595-607.

7. Kaplan N.M. The deadliy quartet: upper - body obesity, glucose intolerance, hipertriglyceridemia and hypertension. Arch Intern Med. 1989;149:1514-20.

8. Haffner S.M., Valdez R.A., Hazuda H.P. et al. Prospective analyses of the insulin resistance syndrome (Synrome X). Diabetes. 1992;41:715-22.

9. Smetnik V.P. Menopausal metabolic syndrome. Lechashchiy Vrach. 2006;10:25-8. (In Russ.).

10. Dedov I.I. Risk factors for coronary heart disease in patients with type 2 diabetes mellitus: the role of hypersympathicotonia and the possibility of its correction. In: Dedov I.I., Aleksandrov A.A., eds. The quality of life. Moscow: MIA; 2003. pp. 16-22. (In Russ.).

11. Demidova T.Y., Ametov A.S., Titova O.I. Current possibilities for the correction of insulin resistance in patients with metabolic syndrome. Ter Arkh. 2006;10:36-40. (In Russ.).

12. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study; a randomized study. Lancet. 2001;357:905-10.

13. Mahbuba S., Mohsin F., Rahat F., Descriptive epidemiology of metabolic syndrome among obese adolescent population. Diabetes Metab Syndr. 2018 May;12(3):369-374. doi:10.1016/j.dsx.2017.12.026.

14. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002 Jan 16;287(3):356-9.

15. Douketis J.D., Sharma A.M. Obesity and cardiovascular disease: pathogenic mechanisms and potential benefits of weight reduction. SeminVasc Med. 2005;5(1):25-33. doi:10.1055/s-2005-871739.

16. Hu G., Qiao Q., TuomilehtoJ. et al. for the DECODE Study Croub. Prevalence of se metabolic syndrome and its relation to all cause and cardiovascular mortality in non diabetic European man and women. Arch Intern Med. 2004;164:1066-76.

17. Ametov A.S., Demidova T.Yu., Tselikovskaya A.L. Obesity and cardiovascular diseases. Ter Arkh. 2001;1:66-9. (In Russ.).

18. Ginzburg M.M. Obesity and metabolic syndrome. Impact on health, prevention and treatment. Samara: Parus; 2000. (In Russ.).

19. Shevchenko OP, Praskurnichyy EA, Shevchenko AO. Arterial hypertension and obesity. Moscow: Refarm; 2006. (In Russ.).

20. Zodionchenko V.S., Adasheva T.V., Demicheva O.Y., et al. Arterial hypertension in metabolic syndrome: pathogenesis, principles of therapy. Consilium Medicum. 2004;6(9):12-6. (In Russ.).

21. Kulikov V.A. Fermingham Heart Study: 65 years of studying the causes of atherosclerosis. Vestnik VGMU. 2012;11(2):16-24. (In Russ.).

22. Shaw J.E., Chisholm D.I. Epidemiology and prevention of type 2 diabetes and the metabolic syndrome. Med J Aust. 2003;179:379-83.

23. Butrova S.A. Metabolic syndrome: pathogenesis, clinical presentation, diagnosis, treatment approaches. Russkiy Meditsinskiy Zhurnal. 2001;2:56-8. (In Russ.).

24. Bachovchin WW, Habener JF. GLP-1(32-36) amide Pentapeptide Increases Basal Energy Expenditure and Inhibits Weight Gain in Obese Mice. Diabetes. 2015;64(7):2409-19. doi:10.2337/db14-1708.

25. Butrova C.A. Insulin resistance syndrome in abdominal obesity. Lechashchiy Vrach. 1999;7:23-6. (In Russ.).

26. Kim M.K., Reaven G.M., Chen Y.I., et al. Hyperinsulinemia in individuals with obesity: Role of insulin clearance. Obesity (Silver Spring). 2015;23(12):2430-4. doi:10.1002/oby.21256.

27. McLaughlin T., Abbasi F., Cheal K., et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003;139(10):802-9. doi:10.7326/0003-4819-139-10-200311180-00007.

28. Sung K.C., Reaven G. Fasting plasma triglyceride concentration: A possible approach to identify increased risk of statin-induced type 2 diabetes. Diab Vasc Dis Res. 2015;12(5):373-6. doi:10.1177/1479164115584275.

29. Giralt M., Villarroya F. White, brown, beige/brite: different adipose cells for different functions. Endocrinology. 2013; 154(9):2992-3000. doi:10.1210/en.2013-1403.

30. Tumova J., Andel M., Trnka J. Excess of free fatty acids as a cause of metabolic dysfunction in skeletal muscle. Physiol Res. 2016;65(2):193-207.

31. Sobenin I.A., Salonen J.T., Zhelankin A.V., et al. Low density lipoprotein-containing circulating immune complexes: role in atherosclerosis and diagnostic value. Biomed Res Int. 2014;2014:205697. doi:10.1155/2014/205697.

32. Marcelino H., Veyrat-Durebex C., Summermatter S., et al. A role for adipose tissue de novo lipogenesis in glucose homeostasis during catch-up growth: a randle cycle favoring fat storage. Diabetes. 2013;62(2):362-72. doi:10.2337/db12-0255.

33. Skolnik E.Y., Marcusohn J. Inhibition of insulin receptor signaling by TNF: potential role in obesity and non-insulin-dependent diabetes mellitus. Cytokine Growth Factor Rev. 1996;7(2):161-73.

34. Lorenzo M., Fernández-Veledo S., Vila-Bedmar R., et al. Insulin resistance induced by tumor necrosis factor-alpha in myocytes and brown adipocytes. J Anim Sci. 2008;86(14 Suppl):E94-104. doi:10.2527/jas.2007-0462.

35. Langlais P., Finlayson Z. Yi, J., et al. Global IRS-1 phosphorylation analysis in insulin resistance. Diabetologia. 2011 Nov; 54(11): 2878-89. doi:10.1007/s00125-011-2271-9.

36. Yadav A., Kataria M.A., Saini V., Yadav A. Role of leptin and adiponectin in insulin resistance. Clin Chim Acta. 2013 Feb 18;417:80-4. doi:2010.1016/j.cca.2012.12.007.Epub2012Dec.22.

37. Dedov I.I., Shestakova M.V., Mayorova A.Yu., eds. Standards of specialized diabetes care. Clinical guidelines. 8th ed. Diabetes Mellitus. 2017;20(1S):1-112. (In Russ.). doi:10.14341/DM20171S8.

38. Seyidova G.B. C-reactive protein and its connection with the metabolic syndrome associated with ischemic disease and the metabolic syndrome of pre-and postmenopausal people. Bulletin of Arrhythmology. 2005;14:47-50. (In Russ.).

39. Bataille R., Klein B. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum. 1992;35:282-3.

40. Torzewski M., Rist C., Mortensen R.F. et al. C-reactive protein in the arterial intima. Role of C-reactive protein receptor-dependent monocyte recruitment in the atherogenesis. Arterioscler Thromb Vase Biol. 2000;20:2094-209.

41. Zwaka T.P., Hombach V., Torzewski J. C-reactive protein-mediated low-density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation. 2001;103:1194-7.

42. Resnick H.E., Hones K., Ruotolo G., et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study. Diabetes Care. 2003;26:861-7. doi:10.2337/diacare.26.3.861.

43. Melnichenko G.A., Pyshkina E.A. Obesity and insulin resistance are risk factors and an integral part of the metabolic syndrome. Ter Arkh. 2001;12:5-8. (In Russ.).

44. Shakhnovich, R.M., Basinkevich, A.B. Markers of inflammation and ACS. Kardiologiya SNG. 2005;3:58-65. (In Russ.).

45. Koening W., Sund M., Fmhlich M. et al. C-reactive protein, a sensitive marker of inflammation, predict future risk of coronary heart disease in initially healthy middle-aged men. Results from MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Ausburg Cohort study, 1984 to 1992. Circulation. 1999;99:237-42.

46. Harris T.B., Ferrucci I., Traxy R.P. et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999;106:506-12.

47. Ford E.S., Giles W.H. Serum C-reactive protein and self reported stroke. Findings from the Third National Health and Nutrition Examination Survey. Arteriocler Thromb Vasc Biol. 2000;(20):1052-1056.

48. Mendall M.A., Strachman D.P., Butland BK. et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardio vascular risk factors in man. Eur Heart J. 2000;2l:1584-90.

49. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N EngI J Med. 2000;342:836-43. doi:10.1056/NEJM200003233421202.


For citation:


Belenkov Y.N., Privalova E.V., Kaplunova V.Y., Zektser V.Y., Vinogradova N.N., Ilgisonis I.S., Shakaryants G.A., Kozhevnikova M.V., Lishuta A.S. Metabolic Syndrome: Development of the Issue, Main Diagnostic Criteria. Rational Pharmacotherapy in Cardiology. 2018;14(5):757-764. (In Russ.) https://doi.org/10.20996/1819-6446-2018-14-5-757-764

Views: 225


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)